DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/c673b1/japan_pharmaceutic) has announced the addition of the "Japan Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.
Japan's pharmaceutical market is proving to be a welcome refuge for the leading multinational drugmakers, which are experiencing austerity-induced revenue contractions in Western Europe and healthcare reform costs in the US. Despite numerous operating challenges in Japan, most notably delays to the introduction of innovative medicines, known as the drug lag', pharmaceutical sales are forecast to remain robust over the medium term.
Headline Expenditure Projections:
- Pharmaceuticals: JPY9,525bn (US$109.3bn) in 2010 to JPY9,961bn (US$126.9bn) in 2011; +4.6% in local currency terms and +16.1% in US dollar terms. The forecast has been revised up from Q411 due to macroeconomic factors, new historic data and additional analyst intervention.
- Healthcare: JPY39,432bn (US$452.3bn) in 2010 to JPY39,718bn (US$506.0bn) in 2011; +0.7% in local currency terms and +11.9% in US dollar terms. The forecast has been revised up from Q411 due to macroeconomic factors.
- Medical Devices: JPY2,755bn (US$31.6bn) in 2010 to JPY2,827bn (US$36.0bn) in 2011; +2.6% in local currency terms and +14.0% in US dollar terms. The forecast has been revised up from Q411 due to macroeconomic factors.
The Japanese economy registered its third consecutive quarter of decline, coming in at 0.5% quarter-on-quarter in Q211 from 0.9% q-o-q in the preceding quarter as the country continued to suffer from the after-effects of the March 2011 earthquake and tsunami. As a result, the author maintains the view that the economy will contract by 0.7% for the whole of 2011.
Companies Mentioned:
- Takeda Pharmaceutical Company
- Astellas
- Eisai
- Daiichi Sankyo
- Mitsubishi Tanabe
- Sawai Pharmaceutical
- Pfizer
- Sanofi
- Merck & Co (Banyu)
- Novartis
- GlaxoSmithKline
- AstraZeneca
For more information visit http://www.researchandmarkets.com/research/c673b1/japan_pharmaceutic